News

NEW YORK, Sept. 9, 2021 /PRNewswire/ — Channel Medsystems, Inc. (“Channel” or “Company”) and InnovaHealth Partners, LP (“InnovaHealth”) jointly announced that InnovaHealth has made a growth equity investment in Channel and acquired a significant interest in the Company. Channel legacy investors, including Third Point, Longwood Fund, and GPG Ventures, also participated in the financing. The growth capital will support the

Sep 08, 2021, 09:00 ET Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer WOBURN, Mass. and JAVENÉ, France, Sept. 8, 2021 /PRNewswire/ Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference. Sight Sciences’ management

MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, today announced publication in Clinical Ophthalmology of favorable 24-month outcomes from a single center open-label study of

MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended June 30, 2021. Recent Business Highlights• Generated second quarter 2021 total revenue of $12.5

CMS issues new HCPCS codes for Dayspring, a novel wearable active compression treatment for lymphedema and venous diseases.   Lymphatic Research and Biology peer-reviewed journal publishes open-label controlled study evaluating efficacy of Dayspring.  OAKLAND, Calif., August 10, 2021 – Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, announced today

More than 35 million Americans have been diagnosed with diabetes, and the country spends Read more…

SAN CARLOS, Calif., June 2, 2021 /PRNewswire/ — Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced the closing of a Series B financing of $10 million. SHD (Scientific Health Development) led the round, with additional investment from GP&G (Green Park & Golf) and other syndicate members. The funds will be used

Dayspring compression therapy system is now FDA cleared for treatment of lymphedema and venous diseases in both upper and lower extremities Koya Medical strengthens leadership team with appointments of three industry veterans to support commercial expansion OAKLAND, Calif., May 26, 2021 — Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and

Pilot CRS Study to Evaluate Performance of Novel Aortix device in Australia and the U.S. HOUSTON, TX – MAY 25, 2021 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the first patients in the company’s pilot trial to evaluate the